Starling Oncology STLNW Estimates

NASDAQ STLNW
$0.04 -0.01 (-21.32%)
As of: Sep 9, 2026 · 12:49 PM EDT
Analyst Estimates

Starling Oncology, Inc. Revenue Estimates

Periods 21
Next Period Q3 26
Consensus 172.63 M

Analysts expect Starling Oncology, Inc. to report revenue of 172.63 M for Q3 26, against a range of 166.95 M to 178.31 M. The most recent reported quarter, Q2 26, came in at 161.28 M, a 1.7% miss against the 163.99 M consensus.

Metric Q4 24Q1 25Q2 25Q3 25Q4 25Q1 26Q2 26Q3 26Q4 26Q1 27Q2 27Q3 27Q4 27Q1 28Q2 28Q3 28Q4 28Q1 29Q2 29Q3 29Q4 29
Reported (Actual) 100.27 M104.41 M119.80 M136.56 M141.96 M147.44 M161.28 M--------
High Estimate 118.20 M-127.24 M135.20 M152.25 M143.53 M171.64 M178.31 M208.42 M202.95 M213.14 M244.39 M260.64 M247.26 M275.89 M
Low Estimate 109.20 M-111.86 M122.06 M134.80 M134.52 M156.33 M166.95 M175.32 M175.52 M186.88 M213.03 M222.87 M228.77 M251.83 M
Consensus Estimate 113.70 M-119.55 M128.63 M143.53 M139.03 M163.99 M172.63 M191.87 M189.23 M200.01 M228.71 M241.76 M238.02 M263.86 M
Analyst Estimates

Starling Oncology, Inc. Earnings Per Share (EPS) Estimates

Periods 22
Next Period Q3 26
Consensus -0.05

Analysts expect Starling Oncology, Inc. to report earnings per share of -0.05 for Q3 26, against a range of -0.05 to -0.05. The most recent reported quarter, Q2 26, came in at -0.08, a 33.3% miss against the -0.06 consensus.

Metric Q3 24Q4 24Q1 25Q2 25Q3 25Q4 25Q1 26Q2 26Q3 26Q4 26Q1 27Q2 27Q3 27Q4 27Q1 28Q2 28Q3 28Q4 28Q1 29Q2 29Q3 29Q4 29
Reported (Actual) -0.18-0.14-0.21-0.15-0.14-0.06-0.02-0.08--------
High Estimate -0.06-0.07--0.12-0.11-0.09-0.09-0.05-0.05-0.01-0.02-0.010.000.050.000.00
Low Estimate -0.08-0.09--0.12-0.11-0.09-0.11-0.07-0.05-0.01-0.02-0.010.000.050.000.00
Consensus Estimate -0.07-0.08--0.12-0.11-0.09-0.10-0.06-0.05-0.01-0.02-0.010.000.050.000.00